Rama Phosphates Q2 FY27 Revenue Hits Record ₹295.5 Cr, PBT ₹26.2 Cr
Rama Phosphates reported record Q2 FY27 revenue of ₹295.5 crore, up 20.3% YoY. PBT rose 14.6% to ₹26.2 crore, and PAT increased 10.9% to ₹19.17 crore. The company's Dhule SSP plant trial run was successful, and Udaipur projects are expected by late November 2026.
The announcement details record financial performance, significant YoY growth, successful plant trial runs, and future project commissioning dates, which are material factors for investors.
The company reported record quarterly revenue and growth in profits, along with successful plant trial runs and upcoming project commissioning, indicating positive operational and financial performance.
Rama Phosphates Limited has announced its financial results for the quarter ended September 30, 2026 (Q2 FY27), reporting the highest quarterly revenue in the company's history.
The company posted a revenue from operations of ₹29,551 Lakhs (₹295.51 crore), marking a significant increase of 20.3% year-on-year and 31.5% quarter-on-quarter. Profit Before Tax (PBT) stood at ₹2,624 Lakhs (₹26.24 crore), up 14.6% YoY and 15.0% QoQ. Profit After Tax (PAT) was reported at ₹1,917 Lakhs (₹19.17 crore), an increase of 10.9% YoY and 12.3% QoQ. Earnings Per Share (EPS) for the quarter was ₹5.42, an 11.1% YoY increase.
For the first half of FY27 (H1 FY27), revenue from operations grew by 19% to ₹52,031 Lakhs (₹520.31 crore), and PBT increased by 11% to ₹4,904 Lakhs (₹49.04 crore).
The company highlighted that the subsidy for H2 FY27 has increased by ₹3,575/MT, from ₹8,149/MT to ₹11,724/MT. The trial run of the SSP plant at the Dhule facility was successfully conducted and is awaiting statutory approvals for full-scale commercial production. The Udaipur new plant projects are expected to be commissioned in the last week of November 2026.
Rama Phosphates maintains an ICRA A-credit rating and is focusing on value-added products. The company's vision includes achieving ₹2,000+ Cr turnover, expanding its fertilizer product portfolio, strengthening market leadership, expanding manufacturing capacity, diversifying products, and promoting sustainable growth.
What to do with a filing like this
Rama Phosphates Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Rama Phosphates Limited. Read the original for the full detail.